Project Description

BioCT MEMBER DIRECTORY
454-sequencing-225px_w

Marinus Pharmaceuticals, Inc.

3 Radnor Corporate Center, Suite 304
Radnor, PA 19087

Phone: 484-801-4670
Fax: 484-801-4659
Website: www.marinuspharma.com

Contact:
Lisa M. Caperelli: Senior Director, Investor Relations & Corporate Communications
– lcaperelli@marinuspharma.com

General Information
Marinus Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company’s clinical stage drug candidate for the treatment of seizure disor-ders in adults and children with epilepsy is ganaxolone. Ganaxolone is a novel synthetic analog of the
endogenous neurosteroid, allopregnanolone (known for its anticonvulsive and antianxiety effects) and was designed to avoid hormonal side effects associated with endogenous neurosteroids. The Company is currently conducting a
multinational, randomized, placebo-controlled, Phase 3 clinical trial to evaluate ganaxolone as adjunctive treatment of partial-onset seizures in adults. Ganaxolone is also being studied in a Phase 2 proof-of-concept clinical study for the treatment of the rare, genetic disorder, PCDH19 female pediatric epilepsy. To complement the existing formulations and to provide continuity of care, the Company is developing an IV formulation of ganaxolone for use in the hospital setting to control epileptic seizures. In addition, ganaxolone is being evaluated in a Phase 2 proof-of-concept investigator-sponsored clinical trial as a treatment for behaviors in Fragile X Syndrome.

> Return to BioCT Member Directory